Therefore, the aim of the present study was to calculate the cumulative lifetime risks for CRC and EC in Lynch syndrome using a cohort of proven MLH1, MSH2 and MSH6 mutation carriers. The gene discussed is MSH6; the disease is colorectal carcinoma.